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Abstract: In this review, we discuss the recent advances in and problems with the use  
of magnetically-guided and magnetically-responsive nanoparticles in drug delivery and 
magnetofection. In magnetically-guided nanoparticles, a constant external magnetic field is 
used to transport magnetic nanoparticles loaded with drugs to a specific site within the body 
or to increase the transfection capacity. Magnetofection is the delivery of nucleic acids under 
the influence of a magnetic field acting on nucleic acid vectors that are associated with 
magnetic nanoparticles. In magnetically-responsive nanoparticles, magnetic nanoparticles 
are encapsulated or embedded in a larger colloidal structure that carries a drug. In this last 
case, an alternating magnetic field can modify the structure of the colloid, thereby providing 
spatial and temporal control over drug release. 
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Nanotechnology is a multidisciplinary branch of science that encompasses numerous fields of science 
and technology, including biomedicine, pharmaceutics, agricultural sciences, environmental sciences, 
advanced materials science, chemistry, physics, electronics, information technology, and others [1].  
In biomedicine, nanoscale materials are of special importance due to their size being compatible with 
cells (10–100 μm), viruses (20–450 nm), proteins (5–50 nm) and genes (2 nm wide by 10–100 nm long). 
Nanomaterials are small enough to move inside the body without disrupting normal functions and can 
access places that are inaccessible to other materials [2]. Cells react in the presence of nanomaterials, 
and these reactions can induce changes in cells, including cell growth or death [3]. 
One of the most commonly-used nanoscale materials are magnetic nanoparticles (MNPs): a type  
of core/shell nanoparticle structure that consists of a magnetic core encapsulated in an organic or  
a polymeric coating. Without a coating, MNPs have hydrophobic surfaces with large surface-to-volume 
ratios and a propensity to agglomerate [4]. MNPs, which exhibit a variety of unique magnetic phenomena 
that are drastically different from those of their bulk counterparts, are generating significant interest, 
since their properties can be utilized in a variety of applications, ranging from storage media for magnetic 
memory devices to probes and vectors in the biomedical sciences [5]. 
The large surface-to-volume ratio of MNPs provides abundant chemically-active sites for biomolecule 
conjugation, thus allowing for precise design and engineering in order for them to meet their  
intended functions, such as long-lasting circulation in the blood stream, target specificity to lesion tissue, 
optical detectability and therapeutic delivery [6,7]. Their magnetic properties enable MNPs to be  
used in numerous applications related to drug and gene delivery, diagnostics and therapeutics. These 
applications can be classed as belonging to one or more of the following groups: 
(1) Magnetic contrast agents for magnetic resonance imaging (MRI). 
(2) Magnetic separation. For this, magnetic beads are functionalized with a biological or chemical 
agent known to bind to a specific target and mixed in a beaker with a solution believed to contain 
the target. After a specific time of contact between the beads and the solution, a permanent magnet 
placed alongside the solution beaker induces a magnetic moment and sets up a field gradient 
across the solution. The targets that have become bound to the magnetized beads are thus 
separated from the bulk solution. 
(3) Immunoassays, where MNPs bound to primary or secondary antibodies are used to separate and 
quantify antigens. 
(4) Hyperthermia agents, where the MNPs are selectively heated by application of a high-frequency 
alternating magnetic field. 
(5) Magnetic vectors that can be directed by means of magnetic field gradients towards a certain 
location, as in the case of the targeted drug delivery. 
Due to the fact that MNPs can be used in both diagnostic and therapeutic applications (Figure 1), they 
are excellent nanosystems with theranostic applications. 




Figure 1. Biomedical applications of magnetic nanoparticles that rely on their magnetic properties. 
Here, we review recent advances in and problems with the development of targeted MNPs (i.e., 
magnetically-guided MNPs, MNPs for magnetofection and magnetically-responsive MNPs). Drug 
transport to specific targets and the ability to control the release of the cargo are two of the most avidly 
pursued goals in drug delivery research. The introduction of nucleic acids into cells is also a field  
of research with numerous therapeutic applications. This review focuses on the use of iron oxide 
nanoparticles (IONs) as particles that, after having been loaded with a drug or nucleic acids, can be 
directed to a chosen site via blood circulation by applying a localized external magnetic field. Furthermore, 
when IONs are encapsulated in some colloidal systems, such as liposomes or gels, the colloidal structure 
may become sensitive to an external magnetic field, and partial modification of the structure can result 
in the controlled release of the encapsulated drug. 
2. Physical Principles of Magnetism 
All materials are magnetic to some extent, with the degree depending on their atomic structure and 
the temperature. Electrons circulating around atomic nuclei, electrons spinning on their axes and rotating 
positively-charged atomic nuclei are all magnetic dipoles, also called magnetons. Altogether, these 
effects may cancel out, so that a given type of atom may not be a magnetic dipole. If they do not fully 
cancel out, however, the atom is a permanent magnetic dipole, as in the case of iron atoms. The strength 
of a magnetic dipole is called the magnetic dipole moment and may be thought of as a measure of the 
capacity of the dipole to align itself with a given external magnetic field. 
When an external magnetic field (H) is applied to a material, the atomic dipoles tend to align 
themselves with the field, thereby causing a magnetic moment within the material. The quantity of 
magnetic moment per unit volume is defined as magnetization (M). 
The relation between magnetization and the magnetic field is given by: =  (1)
where χ is the volumetric magnetic susceptibility, which in SI units is dimensionless, and both M and  
H are expressed in A·m−1. 
Magnetic materials may be conveniently classified in terms of their χ [8]. When the materials exhibit 
weak repulsion (negative susceptibility, with χ in the range −10−6 to −10−3), they are termed diamagnets. 
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If the materials show small positive susceptibility (χ in the range 10−1 to −10−6), they are paramagnets; 
whereas a ferromagnet is a material that exhibits a large positive susceptibility. The magnetic properties 
of the first two categories do not persist if the external magnetic field is removed; while ferromagnetic 
materials have stable magnetic properties even after removal of the external field. A ferromagnet 
becomes a paramagnet above a temperature called the Curie temperature (TC): a temperature at which 
there is a change of the direction of the intrinsic magnetic moments. Below TC, the atoms lose their 
ordered magnetic moments and the material is paramagnetic. 
For diamagnets and paramagnets, the relationship M = χH is usually linear. In contrast, for 
ferromagnets, there is no one-to-one correspondence between H and M, and this relationship is not linear. 
If a paramagnet is demagnetized (H = M = 0) and the relationship between M and H is plotted for 
increasing levels of H, then M follows the initial magnetization curve (dashed line in Figure 2). This 
curve increases rapidly at first and then becomes asymptotic as it approaches magnetic saturation (Ms). 
If H values are reduced monotonically, M follows a different curve (blue line in Figure 2). At H = 0,  
M is offset from the origin by an amount called the remanent magnetization, Mr, which indicates the 
level of residual magnetism in the material. Therefore, the curve, of a sigmoidal shape, tends to a point 
where M = 0. This is called the point of coercivity on the curve. Therefore, the coercivity is the magnitude 
of the field that must be applied in the negative direction to bring the magnetization of the sample back 
to zero. As H increases in the negative direction, the material will again become magnetically saturated, 
but in the opposite direction. Increasing H in the positive direction again will return H to zero, and the 
curve returns to the saturation point (red line in Figure 2), where it completes the hysteresis loop. The 
width of the middle section is twice the coercivity of the material. The area of the hysteresis loop is 
related to the amount of energy dissipated upon reversal of the field. 
Fundamental changes occur in the magnetic structure of macroscopic magnetically-ordered materials 
when their physical size is reduced [4]. In ferromagnetic materials, magnetons are associated in groups 
called domains. A magnetic domain refers to a volume of ferromagnetic material in which all magnetons 
are aligned in the same direction by exchanging forces (Figure 3). A bulk ferromagnet spontaneously 
subdivides into a multidomain structure to reduce the magnetostatic energy associated with a large stray 
field [9]. Within each domain, the magnetization does not vary; but between domains, there are relatively 
thin domain walls in which the direction of magnetization rotates from the direction of one domain to 
that of the other. The formation of the domain walls is a process driven by the balance between the 
magnetostatic energy, which increases proportionally to the volume of material, and the domain wall 
energy, which increases proportionally to the interfacial area between domains. When the size of  
a ferromagnetic material is reduced below a critical value, the so-called critical diameter DCR, more 
energy is required to create a domain wall than to support the external magnetostatic energy of the  
single domain state; the material becomes a single domain. The value of DCR is typically a few tens  
of nanometers and depends on the material. The DCR of a spherical particle is reached when the 
magnetostatic energy equals the interfacial energy. 




Figure 2. M-H curves for a ferromagnetic material. M is the magnetization of the material,  
and H is the external magnetic field. The arrows on the cycle indicate the direction when 
increasing or decreasing the field amplitude. Inset: M-H curve for a superparamagnetic material. 
 
Figure 3. Magnetic regimes of magnetite and maghemite as a function of their size 
(superparamagnetic, single domain, multidomain). 
A single domain particle is uniformly magnetized with all of the spins aligned in the same direction. 
The magnetization will be reversed by spin rotation, since there are no domain walls to move. Further 
reduction in size, below the superparamagnetic diameter DSPM, causes the thermal energy to exceed the 
energy barrier, which separates the two energetically-equivalent easy directions of magnetization  
(the easy axis is the preferred direction of the total magnetization of the dipoles of a given material),  
and the direction of the magnetization fluctuates randomly. Such a system is named a superparamagnet. 
The magnetic moments of individual crystallites compensate for each other, and the overall magnetic 
moment becomes null. When an external magnetic field is applied, the behavior is similar to 
paramagnetism, except that, instead of each individual atom being independently influenced by an 
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external magnetic field, the magnetic moment of the crystallite aligns itself with the field. Consequently, 
superparamagnetic nanoparticles become magnetic in the presence of an external magnet, but revert to  
a non-magnetic state when the external magnet is removed. This is of paramount importance when  
these particles are introduced into living systems (e.g., in drug delivery), because, once the external 
magnetic field is removed, the magnetization disappears (they have negligible remanent magnetization 
and coercivity; see the inset in Figure 2), and thus, agglomeration (and the possible embolization of 
capillary vessels) is avoided [10]. The coercivity is zero for superparamagnets, but it increases in  
the single domain regimen and shows a peak with the development of multiple magnetic domains  
around DCR; then, as the particles reach the micrometer scale, the coercivity essentially becomes the 
same as that of bulk iron. 
The shape of the loops in Figure 2 is determined in part by particle size: in larger particles, with  
a multidomain ground state, the hysteresis loop is narrow, since it takes relatively little field energy  
to make the domain walls move; while in smaller particles, there is a single domain ground state,  
which leads to a broad hysteresis loop. 
Another important property of ferromagnets is magnetic anisotropy, which is the directional 
dependence of their magnetic moments. Whereas for a magnetically isotropic material (i.e.,  
a superparamagnetic material), there is no preferential direction of the magnetic moment, a magnetically 
anisotropic material will align its magnetic moment in one direction, the so-called easy axis. 
Magnetocrystalline anisotropy is derived from spin-orbit coupling. The magnetocrystalline anisotropy 
constant (K) is a physical constant, which reflects the energy required to change the direction of 
magnetization from an easy to a hard axis (energetically unfavorable). The diameters mentioned above, 
DSD and DSPM, can be worked out from K, the dimensionless hardness parameter (κ) and the exchange 
stiffness constant of the material. 
Besides the size, the surface properties of MNPs are essential for their applications. Coating MNPs 
with a layer of a different material is an interesting method for modifying their surface properties. Several 
groups of coating materials are used to modify the surface chemistry of MNPs [11]: 
(1) Organic polymers, such as dextran, chitosan, polyethylene glycol (PEG), polysorbate and polyaniline. 
(2) Organic surfactants, such as sodium oleate and dodecylamine. 
(3) Inorganic metals, such as gold. 
(4) Inorganic, such as silica and carbon. 
(5) Bioactive molecules and structures, such as liposomes, peptides and ligands/receptors. 
Coated nanoparticles have major advantages over simple nanoparticles thanks to their enhanced 
properties, such as: (i) less cytotoxicity; (ii) increased dispersibility and biocompatibility; (iii) better 
conjugation with other bioactive molecules; and (iv) increased thermal and chemical stability [1]. 
For in vivo applications, MNPs need to exhibit high magnetic saturation. Furthermore, there may be 
other requirements depending on the specific application. For instance, the use of nanoparticles as 
external contrast agents for MRI requires nanoparticles with high magnetization; but a small particle size 
is necessary if they must escape from the mononuclear phagocyte system (MPS). Hence, superparamagnetic 
nanoparticles may be the answer. For hyperthermia therapy, ferromagnetic nanoparticles with a large 
area enclosed by their hysteresis loop are the most effective. The potential for magnetic manipulation 
can be the most important property of nanoparticles used as translational vectors in biological 
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applications, such as drug delivery [12] and mechanical cells [13]. The force of attraction that can be 
exerted on MNPs by an external field is given by the equation: = · ∇  (2)
where Fm is the magnetic force experienced by the particle, V the particle volume and B the magnetic 
field intensity. Since, through the volume, the force depends on size, large particles would be necessary 
to ensure a strong attractive force. However, the MNPs must be small enough to remain within the 
superparamagnetism regime. 
3. Iron Oxide Nanoparticles 
Many applications of MNPs still rely on the use of iron oxide particles. Iron oxide can exist in 
different chemical compositions, such as magnetite (Fe3O4) or maghemite (γ-Fe2O3), or, most 
commonly, a non-stoichiometric combination of the two. Magnetite and maghemite are by far the 
materials most frequently used for biomedical applications, and therefore, this review focuses on them. 
The other iron oxides are the ferrites, whose general formula is MFe2O4 (M = Mn, Zn, Co, Ni). 
Magnetite has a cubic inverse spinel structure with a face-centered cubic (fcc) unit cell  
(JCPDS 19-629) composed of 32 O anions, 16 Fe(III) cations and 8 Fe(II) cations. Half of the Fe(III) 
cations are tetrahedrally (tet) coordinated, while the other half and all of the Fe(II) ions are octahedrally 
(oct) coordinated, resulting in a unit cell of (Fe83+)tet(Fe83+ Fe82+)octO32 [14]. Magnetite can be subject to 
oxidation because of the reduced iron in the crystalline lattice. In the presence of oxygen, magnetite 
oxidizes to maghemite. In this process, Fe2+oct is oxidized to Fe3+oct, resulting in vacancies confined  
to the octahedral sites. Accounting explicitly for these vacancies, the unit cell for maghemite  
(JCPDS 39-1346) can be written as (Fe83+)tet(Fe40/33+ □8/3)octO32, where □ refers to a vacant site. It has 
been suggested that an outer coating of maghemite may develop at the particle-water interface during 
magnetite oxidation [15]. Synthetic maghemite often displays superstructure forms, which arise as  
a result of the cations and the vacancy ordering. In that case, the crystalline system changes from cubic 
to tetragonal (JCPDS 25-1402). The extent of vacancy ordering is related to both the crystallite size and 
the amount of Fe(II), or other impurities, in the structure [16]. These possible maghemite arrangements 
are partially responsible for the differences in magnetic behavior manifested by maghemite nanoparticles 
prepared via different routes [17]. 
Because the crystalline structures of magnetite and maghemite are nearly identical, the two oxides 
have very similar physical properties. For instance, the cell parameter, a, is 0.8394 nm for magnetite  
and 0.8346 nm for maghemite. The difference is due to the Fe(II) ions in the structure of magnetite 
having a higher ionic radius than the corresponding Fe(III) ions. Both oxides are considered to  
be ferromagnetic, although magnetite has a larger bulk Ms (92–100 emu/g) than maghemite  
(Ms = 60–80 emu/g) and a lower Curie temperature (TC,magnetite = 850 K, TC,maghemite = 948 K),  
due to antiparallel interactions between the electron spins of tetrahedrally-coordinated Fe3+ and  
octahedrally-coordinated Fe3+/Fe2+ in magnetite [18,19]. Values of Ms depend on the size of the  
particles: Ms decreases as the volume of the particles decreases, although the variation is higher  
when the particles are less than 9 nm in diameter, due to the magnetically-inactive first atomic layer  
at the surface of the particles. This layer, which also exists in bulk materials, has a non-negligible  
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volume in small particles. When the size is greater than 9 nm, Ms is close to the value of the 
corresponding bulk material, especially at sizes greater than from 14 nm, when it reaches 90% of  
the corresponding value for bulk ferromagnetic material at room temperature [20]. 
Below certain sizes, both oxides exhibit superparamagnetic behavior, although their DSPM and DCR 
values are slightly different: 25 nm (magnetite) and 30 nm (maghemite) for DSPM, and 128 nm (magnetite) 
and 166 nm (maghemite) for DCR [21] (Figure 3). 
These two compounds fulfill the prerequisites of: (1) chemical stability under physiological 
conditions; (2) low toxicity; and (3) sufficiently high magnetic moments [22]. 
IONs tend to be classed as superparamagnetic oxides (SPIO), if the individual particles (size of 
core/shell) are larger than 50 nm, or ultra-small superparamagnetic iron oxides (USPIO), for particles 
smaller than 50 nm. 
4. Magnetically-Guided Drug Targeting 
Since the pioneering idea proposed by Freeman et al. [23] that fine iron particles could be transported 
through the vascular system and be concentrated at a particular point in the body with the aid of  
a magnetic field, the use of magnetic particles for the delivery of drugs or antibodies to organs or  
tissues altered by disease has become an active and attractive field of research [24]. The method of  
magnetically-guided drug targeting (MGDT) involves: first, the immobilization of a drug in MNPs; then, 
the injection of the drug/carrier complex into the subject, either via intravenous (i.v.) or intra-arterial 
(i.a.) injection; and, finally, the use of high-gradient external magnetic fields generated by rare-earth 
permanent magnets (generally NdFeB magnets with a maximum surface flux density of a little over  
one T) to guide the complex and concentrate it at the desired locations. Once the complex is concentrated 
at the target in vivo, the therapeutic agent is then released from the magnetic carrier, either via enzyme 
activity or through changes in physiological conditions, such as pH, osmolality or temperature. This 
results in increased uptake of the drug by the tumor cells at the target sites [25] and a limited systemic 
drug concentration [26]. 
The development of magnetically-guided nanoparticles has allowed the usual accumulation of 
nanoparticles observed in particular pathologies, such as tumors, inflammatory and infectious sites,  
to be enhanced. Those pathologies are characterized by structural abnormalities in the vasculature.  
This phenomenon, known as the enhanced permeability and retention (EPR) effect [27], is a consequence 
of the affected tissues possessing “leaky” vasculature, which allows macromolecules and nanoparticles 
to extravasate and accumulate more readily. 
The method of MGDT is not only dependent on physical properties, concentrations and the amount 
of particles applied, but also on the type of binding of the drugs. In addition, the geometry, strength and 
duration of the external magnetic field, as well as the route of ION injection and the vascular supply to 
the targeted tissues will all influence the effects. The physiological parameters of the patient, such as 
body weight, blood volume, cardiac output, peripheral resistance of the circulatory system and organ 
function, will also affect the efficiency of the external magnet; apart from the possibility of placing the 
magnet in close vicinity to the target location [28]. To sum up, the process of drug localization using 
magnetic delivery systems is based on the competing forces exerted on the particles by the blood 
compartment and by the magnetic force generated by the external magnetic field (Equation (2)). 
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Moreover, the administration route of the MNPs seems to be crucial for the success of the therapy, since 
i.a. delivery avoids, or at least minimizes, the particle clearance by the mononuclear phagocyte system 
(MPS) in liver and spleen in comparison to intravenously-applied particles [29]. Preliminary theoretical 
studies of the hydrodynamic conditions of MNP targeting and estimations from experimental work 
indicate that for most magnetic carriers, the field strength (flux density) at the target site should be of 
the order of 200–700 mT with gradients along the z-axis of approximately 8–100 T/m, depending on the 
flow rate (higher blood flow rates require either stronger fields or higher gradients) [30,31]. As a general 
rule, the model indicates that when the magnetic forces exceed the linear blood flow rates in arteries  
(10 cm·s−1) or capillaries (0.05 cm·s−1) [17], the MNPs will be retained at the target site and may be 
internalized by the endothelial cells of the target tissue. Moreover, the results derived from the model 
indicate that magnetic targeting is likely to be more effective for targets that are near the surface and in 
regions of slower blood flow. However, the model is somewhat idealized and limited; a more recent 
model has been developed in which particle capture is modeled for a variety of field/particle 
configurations in a two-dimensional branching network [32]. 
The newer model also incorporates the effects of sheer-induced diffusion due to the presence of cells 
within the blood plasma. The results indicate that it will not be possible to target a specific site in vivo 
without some degree of distribution to the surrounding tissue. For this reason, the authors [32] also 
conclude that magnetic targeting will probably be most effective for targets that are close to the surface 
of the body. 
Although the use of permanent neodymium iron boron magnets in combination with IONs with 
excellent magnetic properties allow the depth of the magnetic field achieved to be increased up to  
10–15 cm [24], the existence of physical constraints on magnetic targeting, such as the rapid drop off of 
field strength with target depth within the body and the difficulties of bypassing intervening vasculature 
and tissue structures [25,33], have hampered the clinical realization of this technology. Much of the 
recent work in this area has focused on the development of high-moment MNP carriers with novel, 
multifunctional coatings and novel techniques for enhancing the body’s own targeting systems [34]. 
Furthermore, progress is being made in improving the delivery of magnetic forces via magnetic needles, 
meshes and bandages, as well as through new methods for creating “stealth” delivery vehicles that use 
magnetic particles incorporated in macrophages or stem cells. One of these improvements is the 
approach referred to as magnetic resonance navigation (MRN), which has been proposed to steer and 
track in real time endovascular magnetic carriers in deep tissues to target areas of interest [35–38] and 
to restrain the systemic carrier distribution. MRN is achieved with a clinical MRI scanner upgraded with 
an insert of steering coils [38,39]. The scanner allows tracking the carrier during MRN along a  
pre-planned trajectory. The magnetic field (1.5 T or higher) of the system enables Ms of ferromagnetic 
materials throughout the body [35,37]. Hence, the problem of a weaker magnetic field in deep tissues 
observed with an external magnet can be overcome. 
A good model for simulating the magnetic properties of MNPs in blood vessels is the “magnetic field 
capture of IONs in flowing systems”. The system consists of a circuit of rubber tubes, pumps and 
magnets, together with a gaussmeter to measure the strength of the magnetic field. It makes it possible 
to simulate the distance necessary to hold and accumulate IONs in moving fluid systems with different 
viscosities (water, glycerol 30%) [28]. An important in vitro study with regard to the simulation of the 
effect of magnetic particles on blood vessels was that carried out by Seliger et al. [40]. They made  
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a circulating system consisting of a circuit with an intact bovine femoral artery close to an external 
magnetic field. After applying the nanoparticle suspensions by a side inlet, they observed that the 
accumulation of nanoparticles and the drug in the target region was higher after the i.a. application 
compared to the i.v. application.  
4.1. In Vitro Studies 
Kellering et al. [41] used an array of permanent magnets consisting of cylindrical NdFeB magnets  
of 4.5 mm diameter arranged with alternating polarity. Flasks containing breast carcinoma cells were 
placed on the magnets, and starch-coated IONs were added. After incubation, the extent of the  
magnetically-induced cell labeling was determined by measuring the iron content of control and labeled 
cells. The results showed that there was selective, higher MNP accumulation within tumor cells, due  
to the effect of the magnets. Along similar lines, Hardiansyah et al. combined chemotherapy and 
thermotherapy using doxorubicin (DOX)-loaded magnetoliposomes (MLPs) and colorectal cancer  
cells (CT-26 cells) [42]. 
Antioxidant enzymes are a promising therapeutic option for pathological conditions involving 
increased production of reactive oxygen species (ROS). However, their efficiency in combating 
oxidative stress is dependent on the ability to achieve therapeutically adequate levels of active enzymes 
at the site of the ROS-mediated injury. Thus, the implementation of antioxidant enzyme therapy requires 
a strategy both for guided delivery to the target site and effective protection of the protein in its active 
form. The utility and therapeutic potential of MNPs for site-specific delivery of biologically-active 
enzymes has remained largely unexplored due to the not inconsiderable challenges involved in the design 
of such formulations. To address those requirements, Chorny et al. developed a magnetic force-triggered 
protein delivery system based on MNPs prepared via the precipitation of calcium oleate in the presence 
of magnetite-based ferrofluid [43]. This system displayed great efficiency in the encapsulation  
of antioxidant enzymes, such as catalase and superoxide dismutase. The authors hypothesized that 
catalase-loaded MNPs applied with a high-gradient magnetic field could rescue bovine aortic endothelial 
cells from hydrogen peroxide toxicity in culture. Their results showed that the approach was not only 
capable of achieving the loading of therapeutically adequate amounts of protein without compromising 
the biological activity, but it could also create a sub-micron-sized, biocompatible carrier structure that 
could provide protection from potential proteolytic deactivation, while allowing permeability for the 
enzyme substrate. 
Cho et al. developed a magnetic switch for the control of cell death signaling [44]. In that work, death 
receptor 4 (DR4) monoclonal antibodies highly expressed on tumor cells were conjugated to MNPs 
(zinc-doped IONs) via a specific antigen-antibody interaction. When applying a magnetic field to the 
aggregate MNP-conjugated DR4s, the magnetic switch is “on”, thus promoting apoptosis signaling 
pathways. The efficacy of the magnetic switch in inducing apoptosis in vivo was evaluated using  
a zebrafish model. An approximately 3.5-fold morphological alteration in the tail region, which was  
a visible consequence of apoptosis signaling, confirmed the occurrence of apoptosis after applying  
a 0.50 T magnetic field for 24 h. 
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Chen et al. prepared a nanoplatform for guided drug delivery by conjugating quantum dots with 
carbon nanotubes filled with magnetite. The platform was capable of transporting DOX into HeLa cells 
by means of an external magnetic field [45]. 
Chiang et al. developed DOX-loaded hollow hybrid nanogels prepared by the coassembly of IONs 
with the graft copolymer comprising acrylic acid and 2-methacryloethyl acrylate units as the backbone 
and poly(ethylene) glycol and poly(N-isopropylacrylamide) as the grafts. With magnetic transport 
guidance toward the target and subsequent exposure to an alternating magnetic field (AMF), this nanogel 
system showed superior cytotoxicity against HeLa cells than free DOX did [46]. 
All of these studies were carried out in 2D cell cultures, and they demonstrate that an external 
magnetic field can assist in the cellular uptake of drug-loaded nanoparticles. Child et al. performed  
a study to establish whether the potential for the combined use of a magnetic field and penetration  
can be successfully applied to cells growing in a 3D environment (a fibroblast-seeded 3D collagen gel). 
Their results showed that magnetic field and cell-penetrating peptides form an excellent partnership  
to achieve therapeutic drug delivery in vivo [47]. 
Another application of the effect of MLPs on cells is a kind of tissue engineering methodology. For 
instance, it is possible to culture keratinocytes and to use them to reconstitute human tissue [48,49].  
Ito et al. showed that keratinocytes labeled with cationic MLPs were accumulated through the use of  
a magnet, and stratification was promoted by a magnetic force, thus forming a sheet-like 3D construct. 
The addition of cationic MLPs to human keratinocytes resulted in the rapid uptake of magnetite 
nanoparticles, and the MLPs accumulated in the keratinocytes reached a maximum of 70% of all of  
the MLPs added [50]. Other studies confirmed that this technique is a promising approach for  
tissue engineering [51–53]. 
More recently, with the aim of overcoming the problems posed by the blood-brain barrier when it 
comes to the transport of drugs into the brain, Thomsen et al. [54] used IONs as drug carriers. The IONs 
were shown to have a significantly increased capacity to penetrate the barrier (human brain microvascular 
endothelial cells) in the presence of an external magnetic force. 
4.2. In Vivo Studies: Animal Models 
4.2.1. Chemotherapy 
Nowadays, one of the most active fields of biomedical research into cancer therapy is the design  
of new anti-tumor devices, and within this context, biocompatible MNPs have innumerous  
applications [55]. The major disadvantage of most chemotherapeutic approaches to cancer treatment is 
that they are non-specific. The i.v. administration of therapeutic (generally cytotoxic) drugs leads to 
general systemic distribution. The non-specific nature of this technique results in the well-known side 
effects of chemotherapy, as the cytotoxic drug attacks normal, healthy cells in addition to its primary 
target: tumor cells. Therefore, MGDT is seen as a potential means of increasing the efficacy and reducing 
the unpleasant side effects associated with chemotherapy, by reducing systemic distribution in 
combination with the possibility of administering lower, but more accurately targeted doses of the 
cytotoxic compounds used in these treatments (Figure 4). 




Figure 4. Schematic representation of the method of magnetically-guided drug targeting. 
Nanoparticles extravasate from pores in leaky tumor blood vessel walls (i.e., enhanced 
permeability and retention (EPR) effect). 
One of the first studies of magnetic targeting of chemotherapy involved the use of a carrier formed 
of albumin microspheres (of several μm in diameter) with entrapped Fe3O4 and DOX that could be 
concentrated at a predetermined site in vivo by a magnetic field. This delivery system allowed for the 
local accumulation of DOX comparable to that achieved by administration of a 100-fold higher dose of 
the free drug [56]. A flood of studies concerning similar drugs using animal models (pigs, rabbits and 
rats) were then reported by several groups, following initial encouraging results [24,57–67]. In 1996, 
Lübbe et al. [68] used IONs coated with starch, to which 4'-epidoxorubicin was chemically bound. The 
drug/carrier was administered via i.v. injection to nude mice and rats and directed into the tumor using 
a magnetic field (permanent magnet; magnetic field strength, 0.5–0.8 T). The drug/carrier was well 
tolerated, and tumor remission was achieved. 
Pulfer and Gallo [69] demonstrated that magnetic microspheres (1–2 μm in diameter) could be 
concentrated at the site of intracerebral rat glioma tumors. Although the concentration of the particles in 
the tumor was low, it was significantly higher than that of non-magnetic particles. In a later study,  
the group demonstrated that 10–20 nm IONs were more effectively targeted at these tumors in rats. 
Electron microscopy analysis of brain tissue samples revealed the presence of magnetic carriers in the 
interstitial space in the tumors, but in normal brain tissue, they were only found in the vasculature [70]. 
Mykhaylyk et al. [71] had less success using magnetite-dextran nanoparticles, but were able to target  
rat glial tumors by disrupting the blood-brain barrier immediately prior to particle injection. 
Magnetoliposomes are a more suitable carrier to transport and deliver a drug, especially due to the 
smaller size of liposomes compared to albumin microspheres. Magnetoliposomes have a typical core/shell 
structure: a magnetic iron oxide core surrounded by an artificial liposome. Viroonchatapan et al. [72] 
designed a study to determine whether dextran-IONs incorporated into liposomes and containing calcein 
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as a fluorescent marker could be targeted at mouse liver with the aid of an extracorporeal magnet. The 
study consisted of an on-line liver perfusion system with a fluorescence detector. The targeting efficiency 
was higher in the presence of a magnetic field. 
As mentioned above, the capture of magnetic particles at a target as a consequence of a magnetic field 
is effective for targets close to the body’s surface; but the magnetic field strength falls off rapidly with 
distance, so sites deeper within the body become more difficult to target. Some groups proposed a way 
around this problem by implanting magnets near the target site, within the body [73,74]. In another study, 
an increase in anti-tumor activity and the elimination of weight-loss as a side effect were reported [75]. 
Similar results were obtained in yet other studies [76]. 
Alexiou et al. [77] treated squamous cell carcinoma in rabbits with mitoxantrone (MTX) bound to 
phosphate groups of MNPs coated with starch derivatives. When the implanted carcinoma had reached 
a volume of ≈3500 mm3, the MNP-MTX was administered via i.a. (femoral artery) or i.v. (ear vein) 
injection, while an external magnetic field was focused on the tumor. The i.a. administration of the 
complex resulted in a significant (p < 0.05), complete and permanent remission of the carcinoma in 
comparison with both the control group (no treatment) and the i.v. group. Typically, 35 days after the 
treatment, the tumor disappeared completely. In addition to this, the dose of the drug applied could  
be diminished to just 20% of the regular systemic dose. No metastases or negative side effects were 
observed. An important advantage of these carriers is the possibility of detecting the nanoparticles after 
treatment with common imaging techniques (e.g., X-ray tomography, magnetorelaxometry, MRI), which 
can be correlated to histology. Studies of the distribution of the particles showed a high accumulation  
of magnetic particles in the tumor region, in contrast to other body compartments (liver or spleen).  
In experiments using radioactive 59Fe-nanoparticles, 114-times more activity was detected in the tumor 
region after MGDT than in the control without a magnetic field [78]. Later, the same group observed 
that the magnetic field caused the drug not only to concentrate in the cancer tissue, but also to penetrate 
the tumor cells. The chemoadsorptive binding was strong enough to be stable during the transport 
process. Desorption occurred with a half-life of about 30 min and released the drug in its active  
form [79]. More recently, Tietze et al. performed a study comparing the biodistribution and therapeutic 
effects of nanoparticle-bound and unbound MTX after i.v. or i.a. administration in rabbits. The study 
showed the advantages of MGDT over the classic chemotherapy [80]. 
Paclitaxel has been one of the most important chemotherapeutic agents against cancer for several 
decades [81]. The drug has been formulated in a vehicle composed of a 50:50 (v/v) blend of Cremophor 
EL (polyethoxylated castor oil) and ethanol. However, the formulation induces histamine release and 
severe allergic reactions [82]. To avoid these undesired effects, paclitaxel has more recently been 
encapsulated in liposomes, with good results both in vitro and in vivo [83]. After i.v. or intraperitoneal 
administration, the paclitaxel-liposome formulations are much better tolerated than paclitaxel in the 
previous vehicle and showed antitumor activity similar to that of the drug in the Cremophor EL/ethanol 
modality. However, liposomes are subject to opsonic phagocytosis by circulating phagocytes and by 
macrophages in liver and spleen. Zhang et al. used magnetoliposomes as a strategy to overcome this 
problem [84]. The formulation was administered via i.v. injection to mice previously inoculated with 
breast tumor cells. Magnetoliposomes were guided and retained at the target site with the help of the 
magnetic field from a circular permanent magnet placed directly on the skin surrounding the tumor mass, 
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via a sterilized rubberized fabric. The results showed that paclitaxel-magnetoliposomes could effectively 
be delivered to the tumor and exerted significant anticancer activity with fewer side effects. 
Béalle et al. prepared non-drug-encapsulating magnetoliposomes. In this case, IONs were 
encapsulated in a volume fraction of up to 30%. The MNPs were rapidly and efficiently internalized  
by cultured tumor cells, and when they were administered to mice, they could be guided to tumors by  
an external magnet [85]. 
Chertok et al. used IONs coated with starch or gum arabic modified with polyethyleneimine (PEI)  
as a potential vascular drug/gene carrier for delivery to brain tumors [86]. The MNPs were injected  
into rats harboring orthotopic gliosarcoma. The intra-carotid administration route was shown to be  
optimal. Although no drug was administered, the study demonstrated that the surface modification  
with polycationic PEI resulted in 5.2-fold higher tumor accumulation of PEI-MNPs compared to 
uncoated MNPs. 
Another kind of MNPs is based on gel combinations. Shen et al. synthesized luminescent MNPs  
with folate-conjugated tetrapeptide composites by in situ assembly for targeted drug delivery to tumors 
(Figure 5). The particles contained: camptothecin (CPT), a broad-spectrum anticancer agent; CdTe 
quantum dots (QDs), a fluorescent dye; magnetite; folic acid, a target ligand with a high binding affinity 
for folate receptors, which overexpresses on the surface of many human malignant cell membranes; and 
finally, chitosan as the gelation material to coat the magnetite and QDs. First, the chitosan, QDs and 
magnetite were directly gelled into ternary hybrid nanogels. Subsequently, the tetrapeptides and folate 
were conjugated in an orderly fashion with the hybrid nanoparticles [87]. 
 
Figure 5. Schematic diagram of the design of multifunctional nanoparticles-tetrapeptide 
folic acid copolymers and their potential applications in biomedicine. GFFG and LGPV  
are the tetrapeptides used as linker molecules (in the single-letter amino acid code:  
GFFG = Gly-Phe-Phe-Gly; LGPV = Leu-Gly-Pro-Val) (reproduced with permission from [87], 
Copyright 2012, American Chemical Society). QD, quantum dot. 
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The resulting MNPs were injected into sarcoma-bearing mice. It was demonstrated that the MNPs 
were trapped in the tumor tissue under external magnetic guidance. Additionally, the study confirmed 
that these MNPs inhibit the growth of cancer cells more than that of normal cells. 
Pouponneau et al. have used the MRN approach to improve drug targeting in deep tissues [88]. They 
used microparticles loaded with iron-cobalt nanoparticles and DOX in rabbits. Rabbits were placed in 
the tunnel of a clinical MRI scanner, and the imaging gradient coils were used to move the MNPs-based 
carriers along a pre-programmed path in the vasculature towards the target site. By performing such 
targeting in the tunnel of a scanner, the MNPs were at saturation magnetization at any depth and, hence, 
did not suffer from the rapid decay that occurs with a permanent magnet placed at the surface. 
4.2.2. Other Biomedical Applications 
Magnetic targeting was also used to break up thrombi. Thrombosis was induced in dog and rabbit 
arteries by surgically inverting a vascular wall flap into the lumen. Once the thrombus had been formed, 
a SmCo magnet was externally secured to one of the arteries. The magnetic field produced by the magnet 
had no effect on the clot formation. Autologous red blood cells loaded with a ferromagnetic colloid 
compound and aspirin were administered intravenously and completely reversed the arteriothrombosis 
in the artery under the effects of the magnet; whereas there was no alteration on clot formation in  
a control artery [89]. Torchilin et al. [90] obtained streptokinase immobilized on dextran-coated 
microparticles of iron oxide, and used this drug/carrier for targeted thrombus lysis in dog carotid arteries. 
After inducing the formation of a thrombus in matching arteries on each side of a dog, a small permanent 
SmCo magnet was implanted into the tissue next to one of the vessels, in the region of the vascular 
surgery and potential thrombus formation. After administration of the thrombolytic preparation, blood 
flow almost completely recovered in the artery with the magnet. 
Integrins are transmembrane receptors that act as cell adhesion molecules. One integrin,  
αVβ3-integrin, is over-expressed in tumor vasculature and invasive tumor cells. A ligand for this integrin 
is the peptide arginine-glycine-aspartic acid (RGD, in the single-letter amino acid code) [91]. Coupling 
RGD onto the surface of any particle facilitates the targeting of tumors and sites of inflammation (rich 
in integrin molecules). Jain et al. [92] used negatively-charged magnetoliposomes, some of them coated 
with RGD peptide and others encapsulating the anti-inflammatory drug diclofenac. They conducted an 
ex vivo study (uptake of neutrophils and monocytes; cells that also express integrin receptors) and an  
in vivo study in rats. It was observed that magnetoliposomes were selectively taken up by the circulating 
blood monocytes/neutrophils, thereby averting uptake by fixed macrophages in the liver. Coating the 
liposomes with RGD peptide further increased their uptake via receptor-mediated endocytosis. This 
uptake, in turn, imparts magnetic properties on these cells, and because of their tendency to migrate 
towards inflammatory sites and under the guidance of an external magnetic field, the drug can actively 
be targeted at any poorly accessible site of inflammation, e.g., brain. Such systems could be useful in the 
treatment of neurological diseases, such as Alzheimer’s disease, Parkinson’s disease, prion disease, 
meningitis, encephalitis, brain tumors, etc., with an inflammatory component. 
Magnetic targeting can also be used to treat inflammatory processes. In an in vivo study, 
magnetoliposomes were administrated via i.v. injection to mice in which an inflammatory focus had 
been induced on their backs. As in cancer pathologies, nanoparticles passively concentrated at the 
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inflammation zone by means of the EPR effect. However, when an external magnetic field was applied 
near the inflammation (Figure 6), that higher amounts of iron were observed in the exudates, while the 
liver, spleen and plasma showed a lower iron concentration than in the absence of the magnet [93]. This 
suggested that the magnet efficiently retained the magnetoliposomes in the inflammation zone. 
 
Figure 6. Experimental device to determine the effect of an external magnetic field on the 
biodistribution of MNPs after i.v. injection into mice in which an inflammatory focus had 
been induced on their backs. Two Nd2Fe12B disk magnets, 25 × 10 mm, of 600 mT per side 
were placed over the hole in the Plexiglas cages. 
4.3. In Vivo Studies in Humans 
As indicated above, numerous small animal studies have been reported. However, due to the technical 
difficulties mentioned (rapidly diminishing field strength with target depth in the body and the 
difficulties of bypassing intervening vasculature and tissue structures), clinical applications largely 
remain a future goal [34]. To date, no application of magnetic targeting in humans has reached the 
marketplace; although some phase I/II clinical trials have been conducted. Lübbe et al. reported the first 
worldwide clinical trials using MGDT [94]. IONs were coated with starch and the resultant complex 
bound to epirubicin through binding the positively-charged amino sugars of epirubicin to the anionic 
phosphate groups of the starch. The trial consisted of i.v. infusion of a chemically-bound drug and one 
course of conventional chemotherapy. During infusion, and for 45 min afterwards, a magnetic field was 
built up as close to the advanced (and unsuccessfully pre-treated) tumor as possible. Though the particles 
accumulated in the liver, the study demonstrated that magnetic carriers were generally well tolerated. 
However, despite the promise of MGDT, there are still several hurdles to overcome prior to achieving 
success in humans, including poor targeting in deep tissue (i.e., >2 cm depth) and poor retention of the 
particles upon removal of the external field [95]. 
At the beginning of 2002, a pharmaceutical company designed magnetic targeted carriers (MTCs) 
composed of elemental iron particles and activated carbon, to deliver drugs to liver cancer patients. The 
MTCs (1–2 µm in size) could adsorb and desorb drugs, such as DOX. A mix of the MTCs and DOX 
was injected into an artery near the tumor, followed by the application of a powerful magnetic field to 
aid the localization and retention of the particles at the targeted site by extravasation of the particles into 
the surrounding tissue. The magnetic field caused the drug to be released into the tumor. When the 
magnetic field was turned off, a high percentage of the particles remained trapped in the tumor, and only 
Int. J. Mol. Sci. 2015, 16 8086 
 
 
a small percentage of the drug circulated throughout the body. Since the total amount was very small, 
there were practically no side effects [26], and hence, the amount of drug necessary was much less than 
had it been dispersed throughout the whole body. However, after a phase III clinical trial, the company 
decided to stop enrolling patients when interim analysis revealed that the goal of the study, to increase 
survival, would not achieve statistical significance. MTCs labeled with β-emitters, such as rhenium-188 
and yttrium-90, were also used in the treatment of liver and brain tumors [96]. 
In 2004, Wilson et al. published encouraging results of a clinical study combining magnetic targeting 
and MRI, in which they were able to monitor the trans-catheter delivery of magnetically-targeted DOX 
to the hepatic artery using intra-procedural MRI [97]. The study demonstrated that there was selective 
targeting of the tumor, with a final fraction of treated tumor volume of 0.64 to 0.91 compared with only 
0.07 to 0.30 for normal liver tissue. 
5. Magnetofection 
The introduction of foreign nucleic acids (plasmid DNA or small interfering RNA (siRNA) 
constructs) into a eukaryotic cell is called transfection. There are two approaches to transfection: viral 
and non-viral. Although viral delivery is the more conventional approach, because viruses have evolved 
to infect cells with a high efficacy, it presents important safety risks. For this reason, for gene therapy, 
attention has focused on non-viral approaches, as these have the potential to overcome many of the 
inherent challenges of viral vectors. Originally, non-viral gene delivery was simply the delivery of naked 
plasmid DNA. To improve the stability and uptake of the DNA, physical strategies (e.g., hydrodynamic 
delivery or electroporation) and specific particles (i.e., cationic polymers, peptides, liposomes and  
solid-core nanoparticles) were developed. One method for attaching DNA to the surface of particles is 
to employ the electrostatic interactions between the negatively-charged phosphate backbone of DNA 
and positively-charged molecules linked to the particle surface. A popular choice for this method is the 
cationic polymer PEI, which facilitates lysosomal release of the complex following internalization  
by buffering the intralysosomal pH and, thereby, causing the lysosome to rupture and release its  
contents [98]. Since it is understood that particle DNA complexes typically enter a cell by endocytosis 
through clathrin-dependent pits [99], it is possible that this feature of PEI will benefit PEI-coated particles. 
A special method of gene delivery is magnetic transfection, or “magnetofection”. Magnetofection is 
the delivery of nucleic acid under the influence of a magnetic field that acts on nucleic acid vectors that 
are associated with MNPs. Magnetofection works along similar physical principles to those of magnetic 
targeting. A high-field, high-gradient magnet is generally placed underneath a cell culture dish or  
multi-well plate. The particle-gene complex is introduced into the cell growth medium, and the magnetic 
field rapidly pulls the particles into contact with the cells growing on the bottom of the dish. The 
efficiency of magnetofection has been demonstrated, since it facilitates the introduction of nucleic acids 
into the nucleus multifold, compared to routinely available standard technologies [100]. 
The first accounts of magnetofection in the literature are conference abstracts by Mah et al. [101] and 
Plank et al. [102] in the year 2000. The first full paper in a scientific journal was by Hughes et al., on 
magnetically-enhanced retroviral nucleic acid delivery [103], followed by the work by Scherer et al. [104] 
on non-viral and viral magnetofection and Mah et al. [105] on recombinant adeno-associated virus 2 
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delivery. Since this pioneering work, there has been a dramatic expansion in work aimed at adapting  
this technique for non-viral transfection of DNA or siRNA [106,107]. 
PEI-coated magnetic particles were first reported by Scherer et al. [104] and provided the first 
example of in vitro MNP-mediated non-viral gene delivery. Since that study, magnetofection has been 
used to transfect a number of cell types, including primary lung epithelial cells [108] and blood  
vessel endothelial cells [109]. Such particles have successfully been used to deliver antisense 
oligonucleotides [110] and siRNA to down-regulate gene expression. Schilinger et al. [99] reported that 
siRNA associated with magnetic particles significantly reduced retrovirally-mediated expression  
of luciferase in HeLa cells. McBain et al. [111] reported an alternative method for synthesizing  
PEI-coated magnetic particles based on covalently coupling PEI to the surface of composite iron  
oxide-dextran silica particles using glutaraldehyde linkers. As mentioned above, PEI has been shown to 
promote the endocytosis of particles, resulting in rapid and efficient transfection [112]. Several groups 
have also successfully employed non-viral nanomagnetic transfection to introduce siRNA into cells for 
gene knockout studies [113]. This involves attaching strands of siRNA to the particles. As the particles 
are taken into the cells, the siRNA blocks the activity of the target gene, knocking out its function. Such 
studies are particularly important for examining the specific genes involved in disease pathways. 
Recently, further advances have been made by using oscillating magnet arrays placed beneath  
the culture dish, as well as pulsed electromagnets oriented perpendicular to the magnetization vector  
of the magnet below the culture dish [114,115]. The oscillations introduce a lateral component of  
motion into the particle-gene complex, which is superimposed on the z-axis motion due to the permanent 
magnet beneath the culture plate. This mechanical stimulation promotes more efficient endocytosis  
of the particle-gene complex and significantly increases transfection efficiency over that of other  
non-viral methods. 
A novel approach examined by Stride et al. combines two physical transfection techniques: 
magnetofection and ultrasound [116]. The transfection efficiency of magnetic microbubble/nanoparticle 
complexes was found to be greater in Chinese hamster ovary cells when both the magnetic field and 
ultrasound were applied simultaneously. This interesting combination of methods may indicate future 
approaches to enhancing non-viral gene transfection, both in vitro and in vivo. As with MGDT, the 
development of magnetic targeting for in vivo gene delivery remains elusive. In a 2006 study,  
Xenariou et al. were not able to demonstrate gene transfection in a mouse model of cystic fibrosis [117]. 
However, in 2008, Hüttinger et al. published the results of a phase I trial of a veterinary application.  
The group showed that magnetofection was well tolerated as a potential gene therapy for feline  
fibrosarcomas [118]. Although the study aimed to evaluate toxicity, 10 of the 20 cats treated were 
recurrence-free after one year; which indicates a potential novel in vivo application of this technology. 
That study may point to a way forward in this area: refining approaches to drug delivery and gene therapy 
in the veterinary field first, as a stepping-stone towards human treatments. 
Magnetofection has significant advantages over traditional transfection methods, including reduced 
process time (of the order of 10 min as opposed to 2–4 h), high transfection rates with lower vector doses 
and an increase in efficacy [119]. Moreover, magnetofection has the major safety advantage that it 
exploits natural uptake pathways (the endocytic mechanisms of cells during the transfection process, 
without disrupting the cell membrane), resulting in high cell viability post-transfection [120,121]. 
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Magnetofection, as a strategy to improve the accumulation of gene delivery vehicles at the tumor site, 
works well for solid tumor masses, but it provides little advantage for highly invasive and infiltrative 
cancers, such as glioma, the most common and lethal type of brain cancers, since the cells of such cancers 
would not be accessible to a magnet. In contrast, chlorotoxin (CTX) is a promising targeting agent due 
to its capacity to specifically recognize a broad spectrum of cancers, including the vast majority of brain 
tumors. Kievit et al. developed a CTX-labeled magnetic nanovector by incorporating the targeting ligand 
CTX onto the surface of a nanovector comprised of an ION core coated with a copolymer of chitosan, 
PEG and PEI. The nanovector effectively bound to DNA. The targeted nanovector was injected into 
mice bearing C6 xenograft tumors. The uptake of the CTX-nanovectors in cancer cells was higher than 
that of the non-targeted vector [122]. 
The major benefits of magnetofection are an improvement in the dose-response relationship in nucleic 
acid delivery, a strong improvement of the kinetics of the delivery process and the possibility of 
localizing nucleic acid delivery in an area that is under the influence of a magnetic field. 
6. Magnetically-Induced Drug Release 
The first use of external magnetic fields to achieve pulsatile release from polymer composites was  
by Kost et al. [123], who observed externally-controlled insulin release from a magnetic composite of 
an ethylene-vinyl acetate copolymer by application of a low-frequency AMF. Even more interestingly, 
however, the inherent thermal energy from MNPs can be used as an external and remote-controlled 
trigger to control drug release. The energy can be used to open the gates for any kind of organic or 
inorganic carriers that contain drugs for therapy. 
Although the first studies conducted to stimulate drug release applied microwave radiation (2.45 GHz) 
to liposomes with enwrapped ferromagnetic microparticles [124], the existence of some drawbacks (e.g., 
the particles presented limited biocompatibility due to their μm range and the surrounding tissue became 
substantially heated) meant that microwaves were substituted by a high-frequency (10–500 kHz) or  
low-frequency (<10 kHz) AMF and ferromagnetic materials by IONs. The AMF can suppress drug-drug 
carrier interactions and accelerate diffusion [125]. The drug release rate is significantly enhanced in the 
presence of a magnetic field, because the pulsatile mechanical deformation generates compressive and 
tensile stresses. Moreover, AMF-triggered drug delivery systems utilize the collapse or volume transition 
of the drug carriers to induce drug release [126]. 
Liposomes are the type of nanoparticles most commonly used for this purpose. Liposomes provide  
a way of dispersing and concentrating nanoparticles and/or drugs via encapsulation or binding, while 
shielding them from biomolecular adsorption. Therefore, nanoparticles or drugs can be delivered  
via established liposome delivery strategies. The simplest way for a drug to be released is by diffusion 
through the lipid bilayer. Diffusion is clearly greatest when the bilayer is disrupted or phase  
separated. Thus, the permeability of the bilayer influences drug diffusion, and the permeability  
of liposomes is greatly enhanced around the membrane melting temperature (Tm) [127], which  
depends on the lipid composition. The cargo can thus be released if the liposome membrane is heated  
to above Tm. For the use of liposomes as thermoresponsive drug delivery vehicles, Tm is typically 
designed to be close to body temperature, to release the cargo at the few degrees higher than the 
temperature of pathological tissue, such as cancer. However, under such circumstances, liposome 
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leakage is produced during circulation. To circumvent the incompatible requirements of simultaneous 
release efficiency and low passive leakage, liposomes have been loaded and decorated with MNPs  
to trigger cargo release under the effect of a high-frequency AMF. Magnetoliposomes were the first 
multifunctional hybrid liposome/nanoparticle assembly and have received considerable attention  
since being introduced in 1988 [128]. 
One of first studies on controlled release from magnetoliposomes was performed by  
Viroonchatapan et al. [129]. Dextran-IONs incorporated in liposomes and containing calcein were 
prepared to study the temperature-dependent release of the fluorescent marker. The thermosensitivity 
and lipid integrity of the magnetoliposomes were not influenced by the inclusion of dextran-IONs. Later, 
Babincová et al. used magnetoliposomes encapsulating DOX and subjected them to the action of an 
AMF (≈1 MHz). The heat generated resulted in the release of the drug from the magnetoliposomes [130]. 
De Paoli et al. demonstrated enhanced dextran release by application of a low-frequency AMF to 
magnetic nanocomposites of collagen [131]. 
Tai et al. [132] entrapped dextran-coated IONs inside thermosensitive liposomes (the lipid composition 
was dipalmitoyl0phosphatidylcholine (DPPC), whose Tm is 41.2 °C). Carboxyfluorescein was used as  
a fluorescent probe to monitor the drug release induced by an AMF. The study was performed in solution, 
in phantom and in rat forearm skeletal muscle and demonstrated that the AMF triggered drug release. 
To improve the sensitivity and responsiveness of MLPs, Chen et al. formed bilayer-decorated MLPs 
containing small hydrophobic SPIO nanoparticles: 5 nm maghemite capped with oleic acid (OA), 
embedded within lipid bilayers [133]. The heating of nanoparticles using alternating current electromagnetic 
fields (AC EMFs) operating at radio frequencies provided selective release of the encapsulated molecule 
at low nanoparticle concentrations and under physiologically-acceptable EMF conditions. Without  
radio-frequency heating, spontaneous leakage from the decorated MLPs decreased with increasing 
nanoparticle loading, consistent with greater bilayer stability and a decrease in the effective decorated 
MLP surface area due to aggregation. With radio-frequency heating, the initial rate and extent of leakage 
increased significantly as a function of nanoparticle loading and EMF strength. The mechanism of 
release is attributed to a combination of bilayer permeabilization and partial decorated MLPs rupture. 
The authors hypothesized that focused heating of embedded nanoparticles could be used to control and 
maximize leakage with minimal nanoparticle loading and EMF strengths. Moreover, nanoparticles can 
be embedded within lipid bilayers without significantly compromising the liposome structure. 
Amstad et al. prepared [134] PEGylated liposomes with a Tm far higher than body temperature that 
hosted individually-stabilized IONs in their membranes in a well-defined structure (Figure 7). IONs  
with an average core diameter of 5 nm were surrounded by a palmityl-nitro dihydroxyphenylalanine  
(DOPA) shell with a dispersant packing density of ~1.5 palmityl-nitro-DOPA/nm2 and mixed with  
2-distearoyl-sn-glycero-3-phosphocholine (DSPC) lipids containing 5 mol % 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG (2)-PE). As a result, the 
liposomes were colloidally stable and impermeable at body temperature. Stable incorporation of IONs 
into liposome membranes allowed repeated, controlled release of the cargo, triggered by an AMF. The 
release efficiency was so high, that it was possible to choose AMF settings to release the cargo without 
increasing the bulk temperature to Tm, even without external cooling. 
  




Figure 7. Schematic of liposomes containing iron oxide nanoparticles (IONs) in their 
bilayer. Palmityl-nitro-dihydroxyphenylalanine (DOPA)-stabilized IONs are embedded in 
liposome membranes consisting of PEGylated and unmodified lipids (reproduced with 
permission from [134], Copyright 2011, American Chemical Society). 
To probe the permeation and actuation of liposomes containing IONs in their membranes, liposomes 
were loaded with the fluorescent probe calcein and then subjected to AMF pulses. After five subsequent 
230-kHz AMF pulses, the fluorescence rapidly increased. Because the liposome structure was retained 
during the AMF treatment, the content could be released repeatedly and non-destructively from 
liposomes at bulk temperatures significantly below Tm of the liposomes. Consequently, the cargo could 
be released over prolonged periods, preventing bursts that can lead to temporary local overdoses. 
More recently, Hardiansyah et al. have combined chemotherapy and thermotherapy using  
DOX-loaded MLPs and colorectal cancer cells (CT-26 cells) [42]. 
Gels are another system used as a stimulus-responsive platform. To enhance the influence of the 
external magnetic or electric fields on the gel properties, it is necessary to combine solid-like and  
fluid-like behavior. Therefore, new colloidal solutions termed “complex fluids” based on ferrofluids and 
polymer gels have been studied. Since polymer gels contain a substantial amount of liquid as a swelling 
agent, it is possible to design field-sensitive gels by using a polymer network swollen in a complex fluid. 
The colloidal particles incorporated within the gel, which are characterized by strong adsorptive 
interactions between solid particles and polymer chains, allow a fast response to an external field.  
These field-sensitive gels can be used to construct new types of controlled delivery systems. In this  
way, IONs have been embedded within hydrogels, and they can carry a therapeutic agent that is released 
upon heating [135,136]. It was observed that pulsatile release from magnetic nanocomposites of gelatin 
hydrogels was obtained by application of a high-frequency AMF [137]. 
Baeza et al. designed mesoporous silica nanoparticles with ION crystals encapsulated inside the  
silica matrix and decorated on the surface with a thermoresponsive copolymer of PEI-b-poly 
(N-isopropylacrylamide) (NIPAM) [138]. The nanocarrier traps the different cargos at low temperatures  
(20 °C) and releases the retained molecules when the temperature exceeds 35–40 °C. This increase in 
temperature can be achieved under the action of an AMF. 
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Devices based on nanocomposite membranes containing thermoresponsive nanogels (usually formed 
of NIPAM) and IONs can provide reversible, on/off drug release upon application (and removal) of  
an AMF. Hoare et al. demonstrated that the dose of drug delivered across the membrane can be tuned 
by engineering the phase transition temperature of the nanogel [139,140]. 
Another strategy for the synthesis of magnetic/polymer nanoparticles involves the precipitation  
of magnetic IONs within a porous polymer microparticle or nanoparticle scaffold [141]. One advantage 
of this technique is that it is often possible to produce particles with a relatively narrow size distribution, 
as well as a well-defined spherical morphology. Specifically, 15 nm (Zn0.4Fe0.6)Fe2O4 nanoparticles  
have been incorporated into porous drug carrier nanoparticles with molecular valves [142]. A molecular 
valve, which consists of a thread and capping molecule (cucurbit[6]uril), closes the silica pores to keep 
the drug inside (Figure 8). 
 
Figure 8. Magnetically-triggered drug release system. Schematics of nanoparticles, 
molecular machines, assembly and remote-controlled drug release. The particles and 
machines are not drawn to scale (reproduced with permission from [142], Copyright 2010, 
American Chemical Society). 
When an external AMF is applied, the generation of heat and subsequent buildup of pressure  
(~90 bar) inside the porous nanoparticles cause the rapid removal of the molecular valves and the release 
of the cargo. These materials are useful for in vivo drug delivery, as demonstrated by the release of  
DOX in breast cancer cells. MNPs were taken up by the cells, and minimal drug release was observed, 
because the valves attached to the surface were closed. In the presence of an AMF, the local heat caused 
by the MNPs facilitated the release of DOX from the silica pores, inducing apoptosis in the cells [142]. 
This result indicates that MNPs are effective as an actuator for controlled drug release from a carrier in 
a non-invasive and remote way. 
A system that combines these two materials and a thermally-sensitive gatekeeper could constitute  
a unique drug delivery system. A novel material that incorporates zinc-doped IONs nanocrystals within 
a mesoporous silica framework that has been surface modified with pseudorotaxanes has been reported. 
Upon application of an AMF, the nanocrystals generate local internal heat, causing the molecular 
machines to disassemble and allowing the cargo (drugs) to be released. When breast cancer cells  
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(MDA-MB-231) were treated with DOX-loaded particles and exposed to an AMF, cell death occurred. 
This material promises to be a non-invasive, externally-controlled drug delivery system with  
cancer-killing properties. 
7. Conclusions 
The development of MNPs has accelerated greatly in recent years due to advances in nanotechnology 
and molecular cell biology. Consequently, various formulations of MNP have been developed for 
theranostic applications. In particular, the use of MNPs as drug carriers has attracted enormous attention. 
However, in relation to magnetically-guided MNPs, efficient in vivo drug delivery is still elusive, with 
fundamental problems being the drop off in magnetic field strength with distance inside the body and 
ever smaller targets, such as individual nanoparticles, as well as the body’s physiological defense 
mechanisms against foreign agents. In contrast, the magnetically-guided approach has yielded clear 
benefits in genic transfection. Compared to all other physical methods, the major advantage of 
magnetofection is that it is capable of combining simplicity, a modest cost, enhanced localization and 
efficiency of delivery and reductions in both incubation time and vector doses. Promising in vivo results 
have also been reported for a pre-clinical trial of gene transfection in cats for the treatment of feline 
fibrosarcomas. Meanwhile, magnetically-sensitive MNPs constitute a platform that shows the highest 
diversity of innovations in the drug delivery field. Apart from the use of thermosensitive liposomes and 
gels that are sensitive to the heat generated by the action of alternating radiation on MNPs, other systems 
have yielded encouraging results. 
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